BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Scott FI, Shah Y, Lasch K, Luo M, Lewis JD. Assessing the Optimal Position for Vedolizumab in the Treatment of Ulcerative Colitis: A Simulation Model. Inflamm Bowel Dis 2018;24:286-95. [PMID: 29361100 DOI: 10.1093/ibd/izx045] [Cited by in Crossref: 12] [Cited by in F6Publishing: 5] [Article Influence: 2.4] [Reference Citation Analysis]
Number Citing Articles
1 Saleh A, Ansari U, Abughazaleh S, Glassner K, Abraham BP. Biological Therapies for the Management of Enteric Disease: Considerations for the Clinician. BTT 2022;Volume 16:67-83. [DOI: 10.2147/btt.s335697] [Reference Citation Analysis]
2 Chu BK, Scott FI, Bewtra M. Optimal Placement of Colectomy in the Treatment of Ulcerative Colitis: a Markov Model Analysis. J Gastrointest Surg 2021;25:3208-17. [PMID: 34725785 DOI: 10.1007/s11605-021-05180-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
3 Abraham B, Glassner K. Positioning biologics and small molecules in the management of moderate to severe ulcerative colitis. Curr Opin Gastroenterol 2021;37:344-50. [PMID: 33731642 DOI: 10.1097/MOG.0000000000000738] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
4 Vachon A, Scott FI. The treatment approach to inflammatory bowel disease in 2020. Curr Opin Gastroenterol 2020;36:247-56. [PMID: 32452863 DOI: 10.1097/MOG.0000000000000653] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
5 Scott FI, Luo M, Shah Y, Lasch K, Vajravelu RK, Mamtani R, Fennimore B, Gerich ME, Lewis JD. Identification of the Most Cost-effective Position of Vedolizumab Among the Available Biologic Drugs for the Treatment of Ulcerative Colitis. J Crohns Colitis 2020;14:575-87. [PMID: 31901085 DOI: 10.1093/ecco-jcc/jjz212] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
6 Uda A, Eto Y, Li Y, Matsuda H, Demiya S, Watanabe T, Ota M, Iwakiri R, Igarashi A. Evaluation of the Optimal Position for Vedolizumab in the Japanese Treatment Paradigm for Ulcerative Colitis Using Markov Modeling. Crohn's & Colitis 360 2020;2. [DOI: 10.1093/crocol/otaa017] [Reference Citation Analysis]
7 Vasudevan A, Ip F, Liew D, van Langenberg DR. The Cost-effectiveness of Initial Immunomodulators or Infliximab Using Modern Optimization Strategies for Crohn's Disease in the Biosimilar Era. Inflamm Bowel Dis 2020;26:369-79. [PMID: 31532479 DOI: 10.1093/ibd/izz159] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
8 Schreiner P, Neurath MF, Ng SC, El-Omar EM, Sharara AI, Kobayashi T, Hisamatsu T, Hibi T, Rogler G. Mechanism-Based Treatment Strategies for IBD: Cytokines, Cell Adhesion Molecules, JAK Inhibitors, Gut Flora, and More. Inflamm Intest Dis 2019;4:79-96. [PMID: 31559260 DOI: 10.1159/000500721] [Cited by in Crossref: 38] [Cited by in F6Publishing: 39] [Article Influence: 9.5] [Reference Citation Analysis]
9 D'Amico F, Fiorino G, Peyrin-Biroulet L, Danese S. Vedolizumab for the treatment of inflammatory bowel diseases: from symptomatic control to mucosal healing. Immunotherapy 2019;11:565-75. [PMID: 30860423 DOI: 10.2217/imt-2018-0209] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
10 Blesl A, Högenauer C, Koch R, Dejaco C, Vogelsang H, Stimakovits J, Fuchssteiner H, Haas T, Petritsch W. Stellenwert von Vedolizumab als Erstlinienbiologikum bei chronisch-entzündlichen Darmerkrankungen (CED). J Gastroenterol Hepatol Erkr 2019;17:10-17. [DOI: 10.1007/s41971-018-0043-9] [Reference Citation Analysis]
11 Pouillon L, Van Stappen J, Bossuyt P, Danese S, Peyrin-Biroulet L. Should we use anti-tumor necrosis factor agents or vedolizumab as first-line biological therapy in ulcerative colitis? Best Pract Res Clin Gastroenterol 2018;32-33:17-25. [PMID: 30060934 DOI: 10.1016/j.bpg.2018.05.006] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]